Drug Profile
JCAR 020
Alternative Names: Anti MUC-16 chimeric antigen receptor T-cell therapy; Anti-MUC16 CAR-T cell therapy-Juno; ET-170; ET170 CAR; IL-12-secreting MUC-16 CAR-T cell therapy; JCAR020; MUC-16-IL-12 armored CAR-T-cells; MUC-16-IL-12-armored chimeric antigen receptor T-cellsLatest Information Update: 10 Oct 2022
Price :
$50
*
At a glance
- Originator Memorial Sloan-Kettering Cancer Center
- Developer Eureka Therapeutics; Juno Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Ovarian cancer
- No development reported Peritoneal cancer
Most Recent Events
- 06 Oct 2022 MUC-16 CAR-T cell therapy is still in phase-I trials for Ovarian cancer in USA (Eureka Therapeutics pipeline, October 2022)
- 28 Jun 2022 No recent reports of development identified for phase-I development in Ovarian-cancer in USA (Parenteral)
- 28 Jun 2022 No recent reports of development identified for phase-I development in Peritoneal-cancer in USA (Parenteral)